Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.

MLA

Stouvenot, Morgane, et al. “Second-Line Treatment after Docetaxel, Cisplatin and 5-Fluorouracil in Metastatic Squamous Cell Carcinomas of the Anus. Pooled Analysis of Prospective Epitopes-HPV01 and Epitopes-HPV02 Studies.” European Journal of Cancer, vol. 162, Feb. 2022, pp. 138–47. EBSCOhost, https://doi.org/10.1016/j.ejca.2021.11.019.

APA

Stouvenot, M., Meurisse, A., Saint, A., Buecher, B., André, T., Samalin, E., Jary, M., El Hajbi, F., Baba-Hamed, N., Pernot, S., Kaminsky, M.-C., Bouché, O., Desrame, J., Zoubir, M., Smith, D., Ghiringhelli, F., Parzy, A., de la Fouchardiere, C., Almotlak, H., & Vienot, A. (2022). Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. European Journal of Cancer, 162, 138–147. https://doi.org/10.1016/j.ejca.2021.11.019

Chicago

Stouvenot, Morgane, Aurélia Meurisse, Angélique Saint, Bruno Buecher, Thierry André, Emmanuelle Samalin, Marine Jary, et al. 2022. “Second-Line Treatment after Docetaxel, Cisplatin and 5-Fluorouracil in Metastatic Squamous Cell Carcinomas of the Anus. Pooled Analysis of Prospective Epitopes-HPV01 and Epitopes-HPV02 Studies.” European Journal of Cancer 162 (February): 138–47. doi:10.1016/j.ejca.2021.11.019.